According to a new report by Polaris Market Research, the global cannabis pharmaceuticals market was valued at USD 5.30 billion in 2024 and is projected to reach USD 357.96 billion by 2034, expanding at a CAGR of 52.4% over the forecast period. Growth is underpinned by rising acceptance of medical cannabis, expanding availability of non-psychoactive CBD-based therapies, and accelerating clinical research investment across key end-use industries.

What Is Driving Cannabis Pharmaceuticals Market Growth?

Demand is climbing as regulatory easing around medical cannabis converges with a growing body of clinical evidence supporting its therapeutic value. Manufacturers and healthcare providers are prioritizing non-psychoactive, CBD-based formulations, pushing cannabis pharmaceuticals adoption across pain management, neurology, and mental health indications. Polaris analysts note that widening healthcare-system acceptance of cannabis-derived medicines positions the industry for sustained triple-digit growth through 2034, with hospitals emerging as an increasingly important channel and online pharmacies remaining the largest point of access.

Key Trends Shaping the Cannabis Pharmaceuticals Industry

Non-Psychoactive Product Innovation

CBD-based medications continue to gain ground on THC-containing formulations as patients and prescribers favor treatments without psychoactive side effects. This shift is reinforced by continued product innovation, with new cannabis-derived formulations targeting epilepsy, anxiety, and sleep disorders entering clinical pipelines.

Expanding Regulatory Acceptance

An evolving regulatory landscape is easing market entry across North America, Europe, and select Asia Pacific markets, allowing broader prescription and distribution of cannabis-based medicines. This regulatory tailwind is a key driver behind the market's aggressive forecast CAGR.

Rising R&D Investment and Consolidation

Public and private funding for cannabis pharmaceutical research is accelerating, supporting an active pipeline of clinical trials. The sector has also seen consolidation activity, including acquisitions among established cannabis companies, as players position for scale ahead of continued market expansion.

Market Segmentation: Breaking Down the Cannabis Pharmaceuticals Market

Polaris segments the cannabis pharmaceuticals market by brand type, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Brand Type

The Epidiolex segment led the market in 2024, supported by its status as the first FDA-approved cannabis-derived medication and its established use in treating certain forms of epilepsy. Sativex, a combined THC/CBD therapy used for multiple sclerosis-related spasticity, holds a stable but smaller position. The Other Brands segment is projected to expand at the fastest pace through 2034 as new cannabis-derived pharmaceuticals advance through clinical trials and regulatory review, broadening the competitive field beyond the two established brands.

By Distribution Channel

Online pharmacies remain the dominant distribution channel, driven by patient demand for discreet, convenient access to cannabis-based medications, especially in regions with established medical cannabis programs. Hospitals represent the fastest-growing distribution channel as cannabis-derived treatments become more integrated into in-patient protocols for chronic pain, cancer-related symptoms, and neurological disorders, signaling where near-term demand for cannabis pharmaceuticals is shifting.

Regional Outlook: Where Is the Cannabis Pharmaceuticals Market Growing Fastest?

North America led the market in 2024, supported by state-level legalization of medical cannabis in the US and regulatory approval of therapies such as Epidiolex and Sativex. Within North America, the United States remains the largest single market, backed by expanding healthcare access and sustained research investment. Europe is registering steady growth as the UK, Germany, and the Netherlands expand access to medical cannabis, with Germany's established regulatory framework positioning it as one of the region's largest markets. Asia Pacific, while still an early-stage market overall, is gaining momentum as countries such as Australia and South Korea legalize medical cannabis, positioning the region as an emerging growth frontier even as markets including China and India maintain more restrictive frameworks.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/cannabis-pharmaceuticals-market 

Competitive Landscape: Leading Cannabis Pharmaceuticals Companies

Key players profiled in the report include GW Pharmaceuticals (now part of Jazz Pharmaceuticals), Tilray, Canopy Growth, and Aurora Cannabis, who are focusing on regulatory approvals, clinical validation, and strategic acquisitions to strengthen market position across the Epidiolex and online-pharmacy-led segments outlined above. Recent moves include HYTN Innovations' July 2025 acquisition of a Cannabis Drug License from Health Canada, expanding its ability to manufacture cannabis-derived pharmaceutical products, alongside continued portfolio consolidation such as Aphria's and Hexo's integration into Tilray, both aimed at deepening share across North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the cannabis pharmaceuticals market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by brand type, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking hospital-channel adoption as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Fired Heaters Market

Regulatory Affairs Outsourcing Market

Non-Linear Optical Crystal Market

Pad-mounted Switchgear Market

Regulatory Affairs Outsourcing Market

Solar Panels Market

5G Infrastructure Market

AI in Governance Market: A Confluence of Economic and Social Influences with this Technology

U.S. Premium Bottled Water Market